Answers are grounded in this paper and cite their sources.
= 298.0 μM in HT-22 neuronal cells was observed. Low metabolic liability was determined in both Phase I and II in vitro models. Throughout these studies other metal binding systems were used for comparison and as appropriate controls. The reactivity reported to date and pharmacological features described herein warrant further studies in vivo and the pursuit of L2 congeners using the knowledge that pyridine substitution in a pyridinophane can be used to tune the structure of the ligand and retain the positive therapeutic outcomes.
No takes yet. Share an insight, caveat, or question.
Green et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: